United States Patent 8,063,031: Scope, Claim-Construct, and Landscape for a Vitreous Dexa/Bioerodible Copolymer Implant
What does US 8,063,031 actually claim?
US 8,063,031 claims a localized intraocular implant for treating an inflammation-mediated ocular condition. The operative claim language ties together four elements:
- Therapeutic cargo: dexamethasone
- Delivery vehicle: a bioerodible copolymer
- Implant placement: the vitreous of the eye
- Pharmacokinetic performance targets in the vitreous:
- Reach an in vivo concentration equivalent to at least 0.05 μg/mL within about 48 hours
- Maintain an in vivo concentration equivalent to at least 0.03 μg/mL for at least about three weeks
Claim 1 (core independent claim)
Claim 1 recites (verbatim substance) an implant comprising:
- dexamethasone + a bioerodible copolymer
- implant structured for vitreous placement
- configured to deliver dexamethasone to vitreous to achieve:
- Cmin threshold: ≥ 0.05 μg/mL by ~48 hours
- duration threshold: ≥ 0.03 μg/mL for ≥ ~3 weeks
This is a product-by-function / performance-defined implant claim: the implant is defined not only by composition and placement, but by drug release performance measured as vitreous concentrations at defined time windows.
How broad is the scope in practice?
1) Composition scope
The claim’s composition limitation is framed as:
- “comprising dexamethasone” and
- “a bioerodible copolymer”
“Comprising” leaves room for additional excipients/components, as long as dexamethasone and a bioerodible copolymer are present. The phrase “bioerodible copolymer” is broader than any single polymer chemistry; it covers multiple copolymer families so long as they are bioerodible and copolymers.
Practical consequence: design-around must focus less on “which polymer” and more on whether the accused device:
- qualifies as bioerodible copolymer, and
- meets the vitreous concentration-time thresholds.
2) Indication scope
The claimed indication is:
- “an inflammation-mediated condition of an eye”
This is not limited to a named disease. It captures a category of ocular inflammatory states. The scope is broad to the extent competitors pursue anti-inflammatory vitreous drug delivery for inflammation-mediated ocular pathology.
3) Anatomical/placement scope
The claim specifies:
- implant placed in the vitreous
This is a strong, physical limitation. If a product is formulated for a different intraocular compartment (for example, suprachoroidal, subretinal, episcleral, anterior chamber) and does not place an implant in the vitreous, it is outside this literal placement requirement.
4) Release-performance scope (the main narrowing feature)
The PK thresholds impose enforceable, measurable constraints:
- Early exposure: ≥ 0.05 μg/mL within ~48 hours
- Sustained exposure: ≥ 0.03 μg/mL for at least ~3 weeks
These thresholds are the practical gatekeeper for both infringement analysis and freedom-to-operate (FTO). Even if the implant is a dexamethasone/copolymer vitreous implant, it may avoid coverage by changing release kinetics such that vitreous concentrations do not meet one or both thresholds.
Summary of scope axes
| Axis |
Claim 1 limitation |
Scope direction |
| Composition |
Dexamethasone + bioerodible copolymer |
Broad (copolymer family not specified in claim text) |
| Implant location |
Vitreous placement |
Narrow (anatomy-specific) |
| Indication |
Inflammation-mediated ocular condition |
Broad (category, not named disease) |
| Release performance |
≥0.05 μg/mL by ~48h; ≥0.03 μg/mL for ≥ ~3w |
Narrow (measurable PK gate) |
What does “equivalent concentration” do to the claim?
The claim language uses “in vivo concentration equivalent.” That term typically captures concentration levels inferred from measurements under an in vivo model or from bioanalytical methods that estimate vitreous exposure. Functionally, it reduces the ability to argue that exact measurement methods were different, if the device nevertheless results in equivalent vitreous exposure.
Enforcement impact: an alleged infringer cannot rely on trivial analytical differences if the device achieves the concentration-time profile in the vitreous.
How does the “about” language affect infringement
The claim uses “about 48 hours” and “about three weeks.” “About” creates flexibility for timing tolerances. It does not remove the requirement, but it widens the window for what counts as meeting the target.
Operational risk: competitors should expect that release kinetics that are close to the thresholds could be asserted as meeting “about” ranges.
Infringement theory: how a plaintiff would frame it
A plausible enforcement pathway focuses on proving all four claim elements:
- The accused product is an implant (not simply a topical drug or injection) with dexamethasone and a bioerodible copolymer
- The product is structured to be placed in the vitreous
- The product delivers dexamethasone to the vitreous achieving:
- ≥0.05 μg/mL by ~48h
- ≥0.03 μg/mL for ≥ ~3 weeks
In litigation, the PK portion is usually the evidentiary center:
- vitreous concentration time-course data (or equivalent modeling)
- implant loading and release rate characterization tied to bioerodible polymer degradation
What claim construction pressure points matter for challengers?
From a challenger’s perspective, the main pressure points are:
- Does the device place an implant in the vitreous?
- A non-vitreal implant is the cleanest path out.
- Does the vehicle use a “bioerodible copolymer”?
- Non-biodegradable matrices and polymer blends that are not “copolymers” can be attacked if a product lacks the requisite polymer classification.
- Do vitreous concentrations actually meet both thresholds?
- A device can still contain dexamethasone and be vitreous-placed but avoid infringement if it does not reach the early threshold or fails the duration threshold.
How does US 8,063,031 compare to common intraocular steroid implants?
The claim aligns with a class of technologies that attempt to solve steroid delivery problems by:
- combining dexamethasone with
- controlled release using biodegradable polymer matrices, and
- targeting vitreous exposure for a sustained anti-inflammatory effect.
The novelty in this claim text is less about “dexamethasone in the eye” and more about the specific combination of:
- vitreous placement
- bioerodible copolymer matrix
- quantified vitreous concentration-time performance targets
Patent landscape: where the claim likely sits in the field
Landscape categories that typically surround this claim
US 8,063,031 sits at the intersection of three patent ecosystems:
- Intraocular steroid delivery
- dexamethasone formulations and delivery devices intended for ocular inflammation
- Biodegradable polymer implants
- controlled-release matrices, including copolymer degradation-controlled release
- Vitreous pharmacokinetics targets
- implant designs that seek sustained vitreous levels while limiting burst and toxicity
Typical design variants that can map to or around the claim
| Variant |
Effect vs Claim 1 |
| Non-vitreal placement (different compartment) |
likely outside literal “vitreous placement” |
| Non-bioerodible matrix |
likely outside “bioerodible copolymer” |
| Bioerodible copolymer but different release kinetics |
risk depends on whether thresholds are met |
| Dexamethasone replaced by different steroid |
avoids “comprising dexamethasone” element |
Practical FTO and freedom-to-operate focus
For products that aim to compete directly in vitreous steroid implants, the claim pushes FTO analysis to PK data:
Minimum evidence set for an infringement or FTO assessment
- Device identity: implant geometry and material composition showing dexamethasone + bioerodible copolymer
- Placement: method and intended surgical placement demonstrating vitreous placement
- PK profile: vitreous concentration-time curve showing:
- ≥0.05 μg/mL within ~48h
- ≥0.03 μg/mL for ≥ ~3w
Early burst vs sustained release tradeoff
The claim is structured so that both early and sustained exposure matter. A competitor can attempt to:
- reduce early burst below 0.05 μg/mL at ~48h, or
- shorten residence so it falls below 0.03 μg/mL before ~3 weeks,
while keeping the overall therapeutic effect in a clinical target profile.
That tradeoff is likely to be the dominant design lever.
Key takeaways
- US 8,063,031 claim 1 is a vitreous-placed, dexamethasone-loaded implant defined by both composition (dexamethasone + bioerodible copolymer) and measurable vitreous PK performance (≥0.05 μg/mL by ~48h; ≥0.03 μg/mL for ≥ ~3 weeks).
- The biggest scope narrowing feature is the concentration-time thresholds, which can be decisive in both infringement and FTO.
- The cleanest design-around is typically to avoid one of the three hard limitations: vitreous placement, bioerodible copolymer, or meeting both PK thresholds.
- For competitors in vitreous steroid implants, the claim shifts evaluation from formulation theory to vitreous exposure proof.
FAQs
1) Does Claim 1 require a specific copolymer chemistry?
Claim 1 text requires a bioerodible copolymer but does not specify a particular copolymer identity. The scope therefore covers multiple bioerodible copolymer chemistries, so long as they meet the bioerodible copolymer requirement.
2) Is the claim limited to a named ocular disease?
No. It covers “an inflammation-mediated condition of an eye,” which is broader than a single named indication.
3) What is the most important infringement element to test?
The decisive element is usually the vitreous concentration-time performance: reaching ≥0.05 μg/mL by ~48 hours and maintaining ≥0.03 μg/mL for ≥ ~3 weeks.
4) Can a product avoid infringement by changing only the release profile?
Yes. A device could still use dexamethasone and a bioerodible copolymer and be placed in the vitreous, but avoid coverage if it does not meet one or both concentration thresholds within the specified time windows.
5) Does “about” expand the claim meaning?
Yes. “About 48 hours” and “about three weeks” introduce tolerance around the specified times, which typically increases litigation risk for “close” release kinetics.
References
[1] United States Patent 8,063,031, Claim 1 (as provided in user prompt).
